Mark Keaton, MD
Hematology & Oncology · Florence, SCNPI 1477530533
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,750 of the $26,425 with a category attached, or 71.0%. 35 manufacturers reported payments, led by AstraZeneca at 51.6% of the total. Reporting peaked in 2024 at $9,432 and has fallen 90.2% since, to $925 in 2025.
Across 242 payments — averaging $109.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- GSK$4K
- Daiichi Sankyo Inc.$2K
- Heron Therapeutics, Inc.$2K
- Novartis$1K
- Merck$444
- plus $3K from 29 others
What the payments were for
- Consulting fees$18,75071%
- Speaking & faculty fees$1,7707%
- Travel & lodging$2,1138%
- Food & beverage$3,77114%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $13,625 |
| GSK | 6 | $4,455 |
| Daiichi Sankyo Inc. | 4 | $1,950 |
| Heron Therapeutics, Inc. | 2 | $1,923 |
| Novartis | 25 | $1,091 |
| Merck | 29 | $444 |
| Amgen | 18 | $329 |
| Cardinal Health 110 LLC | 1 | $275 |
| E.r. Squibb & Sons, L.L.C. | 15 | $215 |
| Novocure GmbH | 1 | $200 |
| Johnson & Johnson(2 entities) | 14 | $199 |
| Sanofi | 8 | $168 |
| Astellas Pharma US Inc | 6 | $161 |
| Puma Biotechnology, Inc. | 7 | $136 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $135 |
| Genentech USA, Inc. | 10 | $133 |
| Eisai Inc. | 7 | $104 |
| Pfizer | 7 | $87 |
| Bristol Myers Squibb | 4 | $87 |
| Gilead(2 entities) | 6 | $83 |
| Tesaro, Inc. | 4 | $79 |
| Incyte Corporation | 5 | $73 |
| Seagen Inc. | 5 | $73 |
| Lilly USA, LLC | 3 | $55 |
| Kyowa Kirin, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Taiho Oncology, Inc. | 2 | $43 |
| AbbVie | 3 | $42 |
| Tersera Therapeutics LLC | 2 | $34 |
| Exelixis Inc. | 2 | $31 |
| EMD Serono, Inc. | 2 | $26 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| Dova Pharmaceuticals | 1 | $19 |
| Array Biopharma Inc | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,425 in reported general payments places this provider in the 85th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Florence
- Rajesh BajajFlorence$10K
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.